Literature DB >> 30195746

Increased circulating regulatory T cells in medicated people with schizophrenia.

Deanna L Kelly1, Xin Li2, Catherine Kilday1, Stephanie Feldman1, Sarah Clark2, Fang Liu1, Robert W Buchanan1, Leonardo H Tonelli3.   

Abstract

Immunological abnormalities are increasingly reported in people with schizophrenia, but no clear functional biomarkers associated with genetic correlates of the disease have been found. Regulatory T cells (Tregs) are key immunoregulatory cells involved in the control of inflammatory processes and their functions are directly related to the human leucocyte antigen (HLA) gene, which has been implicated in schizophrenia genetic studies. However, there is a lack of studies reporting Treg status in people with schizophrenia. In the current study, the proportion of circulating Tregs was examined using flow cytometry in 26 medicated participants with schizophrenia and 17 healthy controls. Psychiatric symptoms and cognitive function were evaluated using the Scale for the Assessment of Negative Symptoms, the Brief Psychiatric Rating Scale, and the MATRICS Consensus Cognitive Battery. The proportion of Tregs was found to be significantly greater in the schizophrenia group compared to healthy controls. No differences were observed in total lymphocyte counts or CD3+ and CD4+ T cells, confirming a specific effect for Tregs. Elevated Tregs in schizophrenia correlated with fewer negative symptoms, a core domain of the illness. These results suggest that Tregs may contribute to improved negative symptoms in schizophrenia, possibly by counteracting on-going inflammatory processes.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Blood biomarkers; CD4 cells; Cognition; Foxp3; Lymphocytes; MHC locus; Schizophrenia biomarkers

Mesh:

Substances:

Year:  2018        PMID: 30195746      PMCID: PMC6207456          DOI: 10.1016/j.psychres.2018.09.006

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  48 in total

1.  Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls.

Authors:  Kristin K Nicodemus; Amanda J Law; Eugenia Radulescu; Augustin Luna; Bhaskar Kolachana; Radhakrishna Vakkalanka; Dan Rujescu; Ina Giegling; Richard E Straub; Kate McGee; Bert Gold; Michael Dean; Pierandrea Muglia; Joseph H Callicott; Hao-Yang Tan; Daniel R Weinberger
Journal:  Arch Gen Psychiatry       Date:  2010-10

Review 2.  How and why do T cells and their derived cytokines affect the injured and healthy brain?

Authors:  Anthony J Filiano; Sachin P Gadani; Jonathan Kipnis
Journal:  Nat Rev Neurosci       Date:  2017-04-27       Impact factor: 34.870

3.  Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls.

Authors:  Marcella Reale; Antonia Patruno; Maria A De Lutiis; Mirko Pesce; Mario Felaco; Massimo Di Giannantonio; Marta Di Nicola; Alfredo Grilli
Journal:  BMC Neurosci       Date:  2011-01-25       Impact factor: 3.288

4.  Neuroinflammation in schizophrenia-related psychosis: a PET study.

Authors:  Janine Doorduin; Erik F J de Vries; Antoon T M Willemsen; Jan Cees de Groot; Rudi A Dierckx; Hans C Klein
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

Review 5.  Major histocompatibility complex I in brain development and schizophrenia.

Authors:  A Kimberley McAllister
Journal:  Biol Psychiatry       Date:  2013-10-10       Impact factor: 13.382

6.  CD4(+) T cells confer anxiolytic and antidepressant-like effects, but enhance fear memory processes in Rag2(-/-) mice.

Authors:  Sarah M Clark; Jennifer A Soroka; Chang Song; Xin Li; Leonardo H Tonelli
Journal:  Stress       Date:  2016-05       Impact factor: 3.493

7.  Novel Foxo1-dependent transcriptional programs control T(reg) cell function.

Authors:  Weiming Ouyang; Will Liao; Chong T Luo; Na Yin; Morgan Huse; Myoungjoo V Kim; Min Peng; Pamela Chan; Qian Ma; Yifan Mo; Dies Meijer; Keji Zhao; Alexander Y Rudensky; Gurinder Atwal; Michael Q Zhang; Ming O Li
Journal:  Nature       Date:  2012-11-07       Impact factor: 49.962

8.  Replication of association between schizophrenia and chromosome 6p21-6p22.1 polymorphisms in Chinese Han population.

Authors:  Yang Zhang; Tianlan Lu; Hao Yan; Yanyan Ruan; Lifang Wang; Dai Zhang; Weihua Yue; Lin Lu
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

9.  Exposure to prenatal infection and risk of schizophrenia.

Authors:  Alan S Brown
Journal:  Front Psychiatry       Date:  2011-11-23       Impact factor: 4.157

10.  Peripheral Immune Cell Populations Associated with Cognitive Deficits and Negative Symptoms of Treatment-Resistant Schizophrenia.

Authors:  Emilio Fernandez-Egea; Petra E Vértes; Shaun M Flint; Lorinda Turner; Syed Mustafa; Alex Hatton; Kenneth G C Smith; Paul A Lyons; Edward T Bullmore
Journal:  PLoS One       Date:  2016-05-31       Impact factor: 3.240

View more
  7 in total

1.  Reduced regulatory T cells with increased proinflammatory response in patients with schizophrenia.

Authors:  Cigdem Sahbaz; Noushin Zibandey; Ayse Kurtulmus; Yazgul Duran; Muazzez Gokalp; Ismet Kırpınar; Fikrettin Sahin; Sinan Guloksuz; Tunc Akkoc
Journal:  Psychopharmacology (Berl)       Date:  2020-03-27       Impact factor: 4.530

2.  Increased random exploration in schizophrenia is associated with inflammation.

Authors:  Flurin Cathomas; Federica Klaus; Karoline Guetter; Hui-Kuan Chung; Anjali Raja Beharelle; Tobias R Spiller; Rebecca Schlegel; Erich Seifritz; Matthias N Hartmann-Riemer; Philippe N Tobler; Stefan Kaiser
Journal:  NPJ Schizophr       Date:  2021-02-03

3.  Contribution from MHC-Mediated Risk in Schizophrenia Can Reflect a More Ethnic-Specific Genetic and Comorbid Background.

Authors:  Lekshmy Srinivas; Neetha N Vellichirammal; Indu V Nair; Chandrasekharan M Nair; Moinak Banerjee
Journal:  Cells       Date:  2022-08-30       Impact factor: 7.666

4.  Schizophrenia Hypothesis: Autonomic Nervous System Dysregulation of Fetal and Adult Immune Tolerance.

Authors:  Tamara Carnac
Journal:  Front Syst Neurosci       Date:  2022-07-01

5.  Psychotropic drugs interaction with the lipid nanoparticle of COVID-19 mRNA therapeutics.

Authors:  Adonis Sfera; Sabine Hazan; Jonathan J Anton; Dan O Sfera; Christina V Andronescu; Sarvin Sasannia; Leah Rahman; Zisis Kozlakidis
Journal:  Front Pharmacol       Date:  2022-09-09       Impact factor: 5.988

Review 6.  The Cross-Talk Between the Dopaminergic and the Immune System Involved in Schizophrenia.

Authors:  Pia M Vidal; Rodrigo Pacheco
Journal:  Front Pharmacol       Date:  2020-03-31       Impact factor: 5.810

7.  Common and disorder-specific upregulation of the inflammatory markers TRAIL and CCL20 in depression and schizophrenia.

Authors:  Flurin Cathomas; Stefan Kaiser; Federica Klaus; Karoline Guetter; Rebecca Schlegel; Tobias R Spiller; Erich Seifritz
Journal:  Sci Rep       Date:  2021-09-28       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.